Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 1, 2014, Pages 81-89

  Diekstra, M H M ^a   Klumpen H J ^b   Lolkema, M P J K ^c   Yu, H ^d   Kloth, J S L ^e   Gelderblom, H ^a   Van Schaik, R H N ^f   Gurney, H ^g   Swen, J J ^a   Huitema, A D R ^d   Steeghs, N ^h   Mathijssen, R H J ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e ERASMUS MC CANCER INSTITUTE   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g MACQUARIE UNIVERSITY   (Australia)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLIZING ENZYME; N DEETHYLSUNITINIB; SUNITINIB;

ABCB1 GENE; ADULT; AGED; ARTICLE; CYP3A4 GENE; CYP3A5 GENE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; GENE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVARIATE ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; INDOLES; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; PYRROLES;

EID: 84902834410     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.47     Document Type: Article

References (34)

1. van Erp, N.P. et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol. 27, 4406-4412 (2009)
2. Garcia-Donas, J. et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 12, 1143-1150 (2011)
3. van der Veldt, A.A. et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 17, 620-629 (2011)
4. Houk, B.E., Bello, C.L., Kang, D. & Amantea, M. A population pharmacokinetic meta-Analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 15, 2497-2506 (2009)
5. Faivre, S. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25-35 (2006)
6. Kulke, M.H. et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 26, 3403-3410 (2008)
7. Lamba, J., Lamba, V., Strom, S., Venkataramanan, R. & Schuetz, E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Dispos. 36, 169-181 (2008)
8. Tang, S.C. et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int. J. Cancer 130, 223-233 (2012)
9. Park, Y.J., Lee, E.K., Lee, Y.K., Park, d.o.J., Jang, H.C. & Moore, D.D. Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice. Toxicol. Appl. Pharmacol. 263, 131-137 (2012)
10. Houk, B.E., Bello, C.L., Poland, B., Rosen, L.S., Demetri, G.D. & Motzer, R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-Analysis. Cancer Chemother. Pharmacol. 66, 357-371 (2010)
11. Rini, B.I. et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 103, 763-773 (2011)
12. Elens, L. et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57, 1574-1583 (2011)
13. Elens, L. et al. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 14, 137-149 (2013)
14. de Graan, A.J. et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin. Cancer Res. 19, 3316-3324 (2013)
15. de Jonge, H., Metalidis, C., Naesens, M., Lambrechts, D. & Kuypers, D.R. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12, 1281-1291 (2011)
16. Elens, L. et al. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet. Genomics 23, 148-155 (2013)
17. Elens, L., van Gelder, T., Hesselink, D.A., Haufroid, V. & van Schaik, R.H. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 14, 47-62 (2013)
18. Xu, C.F. et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J. Clin. Oncol. 29, 2557-2564 (2011)
19. Oneda, B., Crettol, S., Jaquenoud Sirot, E., Bochud, M., Ansermot, N. & Eap, C.B. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet. Genomics 19, 877-883 (2009)
20. Lankheet, N.A., Knapen, L.M., Schellens, J.H., Beijnen, J.H., Steeghs, N. & Huitema, A.D. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther. Drug Monit. (2013); e-pub ahead of print 3 December 2013.
21. Lankheet, N.A. et al. Individual PK-guided sunitinib dosing: a feasibility study in patients with advanced solid tumors. J. Clin. Oncol. 30, 2596 (2012)
22. Kloth, J.S. et al. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun Study. Clin. Pharmacokinet. 53, 261-269 (2014)
23. Kloth, J.S. et al. Effect of dosing time on sunitinib pharmacokinetics. Eur. J. Cancer 49, 692 (2013)
24. de Wit, D. et al. Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemother. Pharmacol. 73, 87-96 (2014)
25. Hansson, E.K. et al. PKPD modeling of predictors for adverse effects and overall survival in sunitinib-Treated patients with GIST. CPT Pharmacometrics Syst. Pharmacol. 2, e85 (2013)
26. Hansson, E.K. et al. PKPD modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST. CPT Pharmacometrics Syst. Pharmacol. 2, e84 (2013)
27. Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11, 274-286 (2011)
28. White-Koning, M. et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin. Cancer Res. 17, 4862-4871 (2011)
29. Klein, K. & Zanger, U.M. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the missing heritability problem. Front. Genet. 4, 12 (2013)
30. Rahmioglu, N. et al. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet. Genomics 21, 642-651 (2011)
31. Gao, B., Yeap, S., Clements, A., Balakrishnar, B., Wong, M. & Gurney, H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J. Clin. Oncol. 30, 4017-4025 (2012)
32. Lankheet, N.A., Steeghs, N., Rosing, H., Schellens, J.H., Beijnen, J.H. & Huitema, A.D. Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring. Ther. Drug Monit. 35, 168-176 (2013)
33. EuroTARGET: TArgeted therapy in Renal cell cancer: GEnetic and Tumour related biomarkers for response and toxicity. European collaborative project funded by the European Commission under the Seventh Framework Programme (FP7)http://www.eurotargetproject.eu/.
34. Purcell, S. et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet. 81, 559-575 (2007).http://pngu.mgh.harvard.edu/purcell/plink/.